

### REMARKS/ARGUMENTS

Upon entry of the amendment claims 3-10 will be pending in the application. Claims 1 and 2 have been canceled without prejudice to the subject matter contained therein. Claims 3, 5, and 7-9 have been withdrawn due to restriction requirement. Claims 4, 6 and 10 are ready for examination. No new matter has been added.

#### Restriction Requirement

The Examiner has set forth a Restriction requirement.

Group I, claims 4, 6 and 10, drawn to a method of treating heart failure with S1P receptor agonist.

Group II, claims 3, 5 and 7-9, drawn to a composition comprising S1P receptor agonist of formulas I-VI.

If Group II is elected, Applicants are required to elect a formula and a specific compound.


#### Election

Applicants elect Group II which is directed to a method of treating heart failure with a S1P receptor agonist. Applicants do not elect a species, since it was not required by the Examiner.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(617) 871-4125

  
Mark W. Milstead  
Agent for Applicant  
Reg. No. 45,825

Date: November 30, 2007